Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that health-related quality of life was generally maintained, and sometimes improved, in patients with HR+/HER2- advanced or metastatic breast cancer treated with palbociclib, compared to monotherapy, across various study types.

In this extended follow-up of the PALOMA-2 trial, no significant differences in overall quality of life were observed between first-line treatments for metastatic breast cancer, but palbociclib plus letrozole showed some benefits regarding side-effects and hair loss.

This study conducted in an Iraqi oncology setting found generic Palbociclib to have a safety profile consistent with previous data, with observed side effects including high rates of neutropenia and anemia, particularly among patients receiving it with Fulvestrant.

This study found that the CDK4/6 inhibitor palbociclib may protect human hair follicles from the damaging effects of taxane chemotherapy by inducing G1 arrest in stem/progenitor cells.

In this study, researchers report that CDK inhibitors like palbociclib and ribociclib, initially developed for cancer therapy, show potential in treating neutrophilic inflammation-related conditions such as ARDS and psoriasis, although their clinical repurposing requires further research on safety and dose adjustments.

This review discusses the use of CDK4/6 inhibitors with endocrine therapy in treating women with HR+ HER2- advanced breast cancer, but it reports no new clinical findings.

This study found that CDK4/6 inhibitors for HR+/HER2- advanced breast cancer are linked to typical adverse events such as fatigue and neutropenia, while also identifying unexpected reactions, highlighting potential safety concerns in their real-world use.

In this study, the researchers found that different CDK4/6 inhibitors used in treating HR+/HER2- advanced breast cancer have varying safety profiles and impacts on patient quality of life.

This study found that scalp cooling resulted in visible hair retention in 53% of breast cancer patients undergoing Epirubicin/Cyclophosphamide and Paclitaxel treatment, with factors like hair bulb diameter, shaft diameter, and anagen rate significantly predicting outcomes.

In this case report, the researchers observed scalp alopecia due to metastasis of breast cancer in a woman in her sixties, highlighting that scalp metastases can result in patchy hair loss and, although often accompanied by poor prognosis, can sometimes show comparatively better outcomes.

This study found that prostaglandin E2 pretreatment may reduce radiotherapy-induced alopecia by enhancing hair follicle self-repair through transient G1 arrest, suggesting a potential preventive treatment.

This study observed that dalpiciclib is associated with fewer adverse events like diarrhea and hepatotoxicity compared to other CDK4/6 inhibitors, potentially offering better patient-perceived safety and quality of life.

This abstract provides information on various oral contraceptives, their potential hazardous interactions, and possible side effects, without presenting new research findings.

This review discusses the diagnosis and treatment of hyperandrogenism in women, emphasizing that cyproterone acetate is effective for severe hirsutism, though it reports no new clinical findings.

This clinical study observed that in patients with advanced breast cancer and BRCA1/2 mutations, talazoparib provided significantly better progression-free survival, objective response, clinical benefit, and patient-reported outcomes compared to physician’s choice chemotherapy, despite common side effects like anemia and fatigue.

This report details a case of hair, nail, and pigmentary disorders occurring 10 months after starting abemaciclib for metastatic breast cancer, highlighting that cutaneous side effects, although less frequent, can lead to discontinuation in 25% of cases.

This study found that using an oral contraceptive with bicalutamide significantly reduced hirsutism in women with PCOS compared to an oral contraceptive alone, although it increased total cholesterol and LDL levels.

This study found that an 8-month treatment with a low-dose oral contraceptive significantly reduced testosterone levels and hair growth in women with polycystic ovary syndrome and hirsutism, with minimal side effects.

This review discusses developments in oral contraceptives, highlighting improved individualization, reduced side effects, and enhanced suitability for various women's health needs, but it reports no new clinical results.

This study found that paclitaxel poliglumex showed limited effectiveness and was relatively well tolerated in post-menopausal women with advanced NSCLC, suggesting further testing of this treatment may not be justified.

Some birth control pills increase blood clot risk; use them for specific conditions only.

This study found that CDK4/6 inhibitors in hormone-positive metastatic breast cancer were linked to increased risks of fatigue, alopecia, and stomatitis compared to placebo.

This article discusses the potential of oral bicalutamide as a promising treatment for female pattern hair loss and reports no new clinical results.

In this study involving women undergoing taxane-based chemotherapy, a twice-daily topical application of BPM31543 was well-tolerated and showed potential in reducing severe hair loss, prompting further investigation at higher doses.

The document concludes that scalp cooling and treatments like minoxidil can help manage hair loss from cancer therapy.

This study found that 49% of female breast cancer patients treated with CDK4/6 inhibitors for at least three months developed alopecia, which significantly impacted their quality of life, with greater alopecia severity leading to worse emotional and functional well-being.

In this study, COC treatment led to greater improvements in sex hormone, endocrine factor, and metabolic levels among PCOS patients compared to those who did not receive the treatment.

This study found that applying BPM 31543 twice daily was safe, well-tolerated, and showed signs of reducing chemotherapy-induced alopecia in women receiving taxane-based chemotherapy.